51591-89-0

Usage

Uses

Used in Cancer Treatment:
Amifostine is utilized as a chemoprotective agent for cancer patients undergoing specific types of chemotherapy. It is particularly effective in reducing the toxic effects of certain chemotherapy drugs on normal tissues, thereby lowering the risk of side effects like kidney damage and nerve damage. Amifostine is typically administered by injection before the commencement of chemotherapy.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, amifostine is used as an active pharmaceutical ingredient in the formulation of medications aimed at providing protection to healthy cells during cancer treatment. Its role in mitigating the side effects of chemotherapy makes it a valuable component in the development of supportive care pharmaceuticals for cancer patients.
Used in Clinical Research:
Amifostine is also employed in clinical research as a subject of study for its potential applications in reducing the harmful effects of chemotherapy on normal tissues. Researchers investigate its mechanisms of action, efficacy, and safety profile to further understand its role in cancer treatment and explore possible enhancements to its chemoprotective properties.

InChI:InChI=1/C10H15NO4S/c1-16(14,15)8-4-2-7(3-5-8)10(13)9(11)6-12/h2-5,9-10,12-13H,6,11H2,1H3

Upstream product

• 91645-98-6 (1RS,2RS)-2-acetylamino-1-(4-methanesulfonyl-phenyl)-propane-1,3-diol 
• 96795-22-1 (4S,5S)-4-Hydroxymethyl-5-(4-methanesulfonyl-phenyl)-oxazolidin-2-one 
• 108565-01-1 N-[1-hydroxymethyl-2-(4-methanesulfonyl-phenyl)-2-oxo-ethyl]-acetamide 
• 38423-42-6 N-[1-hydroxymethyl-2-(4-methylsulfanyl-phenyl)-2-oxo-ethyl]-acetamide 
• 408352-71-6 2-amino-1-(4-(methylmercapto)phenyl)ethanone 
• 23150-33-6 (1RS,2RS)-2-acetylamino-1-(4-methylsulfanyl-phenyl)-propane-1,3-diol 
• 56739-66-3 N-(4-methanesulfonyl-phenacyl)-acetamide 
• 115475-67-7 Benzoic acid (S)-(4-methanesulfonyl-phenyl)-((S)-2-oxo-oxazolidin-4-yl)-methyl ester 
• 847-25-6 (+/-)-Thiamphenicol 
• 31925-27-6 DL-threo-p-methylsulfonylphenylserine ethyl ester 
• 36983-12-7 D-threo-p-methylsulfonylphenylserine ethyl ester 
• 14052-59-6 D-threo-1-p-methylmercaptophenyl-2-dichloroacetamidopropane-1,3-diol 
• 119293-92-4 (+/-)-2-dichloroacetamido-β-hydroxy-4-methylmercaptopropiophenone 
• 7780-07-6 (+/-)-threo and (+/-)-erythro-1-p-methanosulfonylphenyl-2-dichloroacetamido-1,3-propanediol 

Downstream Products

• 19934-71-5 2,2-dichloro-N-{1,3-dihydroxy-1-[4-(methylsulfonyl)phenyl]propan-2-yl}acetamide 
• 847-25-6 (+/-)-Thiamphenicol 
• 51458-28-7 (1R,2R)-2-amino-1-<4-(methylsulphonyl)phenyl>-1,3-propanediol 

Relevant academic research and scientific papers

Preparation method of florfenicol

The invention relates to a preparation method of florfenicol, which belongs to the technical field of medicine synthesis. The preparation method adopts D-p-methylsulfonyl-phenylserine ethyl ester as a raw material to be subjected to reducing reaction, cyclization reaction, fluoridation and hydrolytic reaction to prepare the florfenicol. In the fluoridation, dichloromethane is used as a solvent, a cyclization product and a fluoridation reagent are used as reaction raw materials, and the mass ratio of the cyclization product to the fluoridation reagent is (1.25 to 1.30) to 1. The preparation method has the advantages of simple process operation and low cost. By controlling a reaction condition and using additives, byproducts of the fluoridation are reduced, so that a florfenicol product with high purity and fewer impurities can be obtained only by virtue of one-step decoloration and refining step, the product cost can be controlled, and the production efficiency can be improved.

Reversed-phase liquid chromatographic separation of enantiomeric and diastereomeric bases related to chloramphenicol and thiamphenicol.

The important antimicrobial agents chloramphenicol and thiamphenicol are N-acylated amines whose chemical structures include two chiral centers. Each drug is the single enantiomer of R,R configuration. The N-deacylated bases of the drugs are important intermediates in their synthesis and optical resolution. In this report, reversed-phase HPLC methods are described for the separation of enantiomeric and diastereomeric bases of the two drugs and of two closely related bases used in some syntheses of the drugs. The stereoisomeric bases were derivatized with a homochiral isothiocyanate and the resulting diastereomeric thioureas were separated on C18 columns with methanol:water mixtures as mobile phases and detection at 254 nm. The four stereoisomeric bases of chloramphenicol and those of its unnitrated analogue were thus separable after derivatization with 2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl isothiocyanate. This reagent also allowed the separation of the D-threo isomer of the p-mercaptomethyl analogue of thiamphenicol base from its stereoisomers. The stereoisomers of thiamphenicol base were similarly separated with (R)-alpha-methylbenzyl isothiocyanate as the derivatizing agent. The diastereomers of chloramphenicol base and of thiamphenicol base were chromatographically separable after derivatization with the nonchiral reagent benzyl isothiocyanate. The procedures developed may be useful in the determination of the stereoisomeric composition of the drugs in research and in quality control, and may be applicable to other similar agents whose chemistry and pharmacology are receiving considerable attention.

CYCLOFUNCTIONALISATION REACTIONS OF EPOXYALCOHOL DERIVATIVES. 3. CYCLISATION-ACYL MIGRATION OF N-BENZOYLCARBAMATES TO STEREODEFINED OXAZOLIDINONES. A NEW, DIASTEREOSPECIFIC ROUTE TO THIAMPHENICOL.

N-Benzoylcarbamates formed in situ from 2,3-epoxyalcohols and PhCONCO undergo clean to C-2 cyclisation followed by N to O acyl migration on treatment with catalytic sodium imidazolide or other bases.Subsequent benzoate cleavage (NaOMe) is accompanied by equilibration of the N-unsubstituted oxazolidinones; cleavage without significant isomerisation is achieved with MeLi or Zn(BH4)2.This methodology is applied in a diastereospecific, 6-step conversion of methyl 4-bromophenyl sulfonate to racemic Thiamphenicol.